公告提醒：愛必信所有產(chǎn)品和服務(wù)僅用于科學(xué)研究，不用于臨床應(yīng)用及其他用途提供產(chǎn)品和服務(wù)（也不為任何個人提供產(chǎn)品和服務(wù)）!

抑制劑描述：

產(chǎn)品名稱：Paclitaxel

產(chǎn)品別名：紫杉醇

英文別名：NSC 125973;Taxol

靶點(diǎn)：Microtubule (human endothelial cells)

CAS：33069-62-4

純度：>99 %

外觀：Lyophilized powder

保存方法：store at -20℃ for one year（Powder）； in DMSO or others solvent store at 2-4℃ for two weeks, at -20℃ for six months.

描述：

Paclitaxel (紫杉醇) 是微管聚合穩(wěn)定劑，IC50是0.1 pM。Paclitaxel 是有絲分裂抑制劑。

溶解性：DMSO：171 mg/mL (200.25 mM)
Ethanol：18 mg/mL (21.07 mM)

體外研究：

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells.

體內(nèi)研究：The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively.

產(chǎn)品信息訂購：

產(chǎn)品更多信息請進(jìn)入愛必信網(wǎng)站咨詢